CJC-1295 with DAC

DAC:GRF · Drug Affinity Complex CJC-1295

Rank#999
Growth HormoneNot ApprovedPhase IIResearchSubQ

Popular for:Long-acting GH elevation, less frequent dosing, sustained IGF-1 increase

0

Total Studies

0

Human Studies

Phase II

Evidence Level

Not Approved

FDA Status

Overview

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone analog that binds to albumin in the bloodstream, extending its half-life from ~30 minutes (without DAC) to 6-8 days. This allows for once or twice weekly dosing instead of multiple daily injections.

The DAC modification fundamentally changes the pharmacokinetics — instead of producing acute GH pulses like standard CJC-1295 (Mod GRF 1-29), the DAC version creates sustained, elevated GH levels. This difference is significant: pulsatile release mimics natural physiology, while sustained elevation does not. Researchers debate which approach is preferable.

Mechanism of Action

The DAC moiety is a lysine linker with a maleimidopropionic acid group that covalently bonds to albumin after injection. This albumin binding protects the peptide from enzymatic degradation and renal clearance, extending its half-life dramatically. The GHRH analog portion still activates GHRH receptors on pituitary somatotrophs, but the sustained presence means continuous rather than pulsatile GH stimulation.

Key Research Benefits

Extended half-life (6-8 days) — once or twice weekly dosing
Studied for sustained GH and IGF-1 elevation
Convenience over multiple daily injections
Clinical trial data available (ConjuChem Biotechnologies)
Researched for body composition and recovery

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

0

Total Studies

0

Human Studies

Not FDA-approved. Was in clinical trials by ConjuChem Biotechnologies. Research compound. Often compared unfavorably to non-DAC version due to non-pulsatile release pattern.

Key Studies / PubMed References

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Review

Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026

PMID: 41490200

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Review

Mayfield CK, Bolia IK, Feingold CL, et al. · The American journal of sports medicine · 2026

PMID: 41476424

Advances in the detection of growth hormone releasing hormone synthetic analogs.

In Vitro

Memdouh S, Gavrilović I, Ng K, et al. · Drug testing and analysis · 2021

PMID: 34665524

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

Review

Timms M, Ganio K, Forbes G, et al. · Drug testing and analysis · 2019

PMID: 30489688

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

Review

Timms M, Ganio K, Steel R · Drug testing and analysis · 2019

PMID: 30938069

Side Effects & Safety

Water retention and bloating (more than non-DAC version)
Headache
Flushing
Potential for GH-related side effects from sustained elevation (joint pain, carpal tunnel)
Less physiological than pulsatile release — continuous GH elevation is not natural

Known Interactions

No curated interaction entry is live for CJC-1295 with DAC yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. CJC-1295 with DAC is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.